Results of cebranopadol, a first-in-class, dual NOP/MOP receptor agonist for acute pain after abdominoplasty and bunionectomy (PAINWeek 2026) - Aug 4, 2026 - Abstract #P084 - (Poster #84); Pres time: Sep 10, 2026; 05:30 PM - 07:00 PM; Location: Exhibit Hall - Belmont Ballroom (Level 4); P3 | "In ALLEVIATE-1, a significant reduction in NRS AUC 4-48 was observed with cebranopadol 400µg vs. placebo (LS mean difference -59.2; p< 0.001). In ALLEVIATE-2, a significant reduction in NRS AUC 2-48 occurred with cebranopadol 400μg vs."
Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain
|
|
Todd Bertoch, MD; Megan Shram, PhD; James Hackworth, PhD; Joseph C. Grieco, PhD; Harold Minkowitz, MD
|